Success Stories: EB-1A Approved for Chemical Biology Researcher Advancing Small-Molecule Design and Molecular Imaging
Client’s Testimonial:
“Thank you for the prompt information! It has been a great pleasure working with you and your team at We Green. I truly appreciate the support and professionalism throughout the process.”
On August 1st, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Visiting Postdoctoral Fellow in the field of Chemical Biology (Approval Notice).
General Field: Chemical Biology
Position at the Time of Case Filing: Visiting Postdoctoral Fellow
Country of Origin: China
State of Residence at the Time of Filing: Maryland
Approval Notice Date: August 1st, 2025
Processing Time: 1 month, 26 days (Premium Processing Requested)
Case Summary:
We are pleased to share the success story of an EB-1A petition approval granted to a visiting postdoctoral fellow whose pioneering work in small-molecule design, protein engineering, and bioluminescent imaging has produced transformative tools for probing cellular processes and advancing therapeutic discovery.
Research Focus and Contributions
The petition highlighted the client’s innovative research program, which includes:
- Engineering metabolic chemical reporters to map post-translational histone modifications in living cells
- Developing red-shifted bioluminescent sensors for functional brain imaging and high-sensitivity bioassays
- Creating novel coelenterazine-based probes to enable deep-tissue tumor imaging with enhanced resolution
To demonstrate extraordinary ability, the petition assembled key quantitative metrics:
- 12 peer-reviewed journal articles documenting first-in-field structural and imaging advances
- 455 total citations, placing the researcher among the top 1 percent most-cited authors in bioluminescence and chemical biology
- At least 65 invited manuscript reviews for high-impact journals, confirming recognition as a field authority
“Despite the high costs and limited accessibility of advanced imaging modalities like immuno-PET, the [client’s] work on novel bioluminescence pairs and an immunobioluminescence platform offers a more affordable, reliable alternative, democratizing access to cutting-edge imaging for researchers and clinicians alike.”
Demonstrating Extraordinary Ability
The petition provided evidence of independent adoption of the client’s imaging tools by global research teams and extensive peer review and editorial board service for leading journals. A final merits determination aggregated these criteria and confirmed that the client ranks among the very small percentage at the pinnacle of chemical biology.
Well Positioned for Continued Innovation
The petition documented the client’s advanced training (Ph.D. in chemical biology), extensive postdoctoral and staff-scientist experience, and leadership of multidisciplinary collaborations to translate bespoke molecular tools into preclinical and clinical applications, establishing a strong foundation for future breakthroughs in therapeutic development.
Approval and Outcome
Filed June 6, 2025, under direct premium processing, and approved August 1, 2025, in just 1 month and 26 days, this EB-1A approval underscores the United States’ commitment to retaining exceptional talent in critical scientific fields. NAILG is proud to have guided this client through a seamless EB-1A process and looks forward to supporting ongoing contributions to global health innovation.